Stay updated on Lecanemab Safety, Tolerability & Efficacy in Early Alzheimer's Clinical Trial
Sign up to get notified when there's something new on the Lecanemab Safety, Tolerability & Efficacy in Early Alzheimer's Clinical Trial page.

Latest updates to the Lecanemab Safety, Tolerability & Efficacy in Early Alzheimer's Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedAdded official results data and expanded safety/efficacy endpoints for core and extension phases, including ADCOMS, CDR-SB, ADAS-Cog, CSF biomarkers, MRI volumetrics, and amyloid PET measures; TEAEs/SAEs definitions and the Results First Posted date are now included.SummaryDifference2%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedRevision tag updated from v3.4.1 to v3.4.2 with no substantive content changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check39 days agoChange DetectedA new revision tag v3.4.1 was added and the previous v3.4.0 tag removed. No visible changes to core study content or functionality.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision: v3.3.4 has been added, replacing Revision: v3.3.3.SummaryDifference0.0%

- Check83 days agoChange DetectedExpanded the study locations to include numerous sites across the United States, Canada, and Europe (e.g., Alabama, Arizona, California; Ontario, Quebec; Paris; Berlin; etc.). It clarifies where recruitment and participation are possible.SummaryDifference2%

- Check90 days agoChange DetectedResults Submitted has been added and No Results Posted has been removed. This indicates that the study's results have been submitted for public listing.SummaryDifference0.0%

Stay in the know with updates to Lecanemab Safety, Tolerability & Efficacy in Early Alzheimer's Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lecanemab Safety, Tolerability & Efficacy in Early Alzheimer's Clinical Trial page.